Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

DNP-modified autologous renal cell carcinoma tumor cell vaccine

A cancer vaccine consisting of autologous renal cell carcinoma (RCC) tumor cells modified with the hapten 2,4-dinitrophenol (DNP) with potential immunostimulating and antineoplastic activities. Administration of DNP-modified autologous renal cell carcinoma tumor cell vaccine may induce a cytotoxic T-lymphocyte (CTL) response against renal cell carcinoma tumor cells. DNP conjugation may enhance the immunogenicity of weakly immunogenic antigens.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:dinitrophenyl-modified autologous renal cell carcinoma tumor cell vaccine
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search